ストックスクリーナーアプリを入手
1.55
4.73%
0.07
アフターアワーズ：
1.49
-0.06
-3.87%
前日終値:
$1.48
開ける：
$1.5
24時間の取引高:
222.35K
Relative Volume:
0.37
時価総額：
$46.79M
収益：
$1.05M
当期純損益:
$-48.82M
株価収益率:
-0.847
EPS:
-1.83
ネットキャッシュフロー:
$-47.49M
1週間 パフォーマンス:
+3.33%
1か月 パフォーマンス:
+19.23%
6か月 パフォーマンス:
-13.89%
1年 パフォーマンス:
-82.25%
1日の値動き範囲:
$1.47
$1.59
1週間の範囲:
$1.35
$1.59
52週間の値動き範囲:
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
ATNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.55 | 46.79M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM - ACCESS Newswire
2025-05-12 | Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM | NYSEAM:ATNM | Press Release - Stockhouse
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - The Victoria Advocate
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action ... - Bluefield Daily Telegraph
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - GlobeNewswire Inc.
Actinium Pharma (ATNM) Receives Buy Rating with $4.00 Price Targ - GuruFocus
Actinium Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your RightsATNM - PR Newswire
Investors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class ActionATNM - ACCESS Newswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending - GlobeNewswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - GlobeNewswire Inc.
2025-05-10 | Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline | NYSEAM:ATNM | Press Release - Stockhouse
2025-05-09 | Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM | NYSEAM:ATNM | Press Release - Stockhouse
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATNM Stock News: Actinium Pharmaceuticals, Inc. Investors Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the ATNM Class Action - ACCESS Newswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit - Business Wire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium - GlobeNewswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for InvestorsContact The Gross Law Firm - Morningstar
Contact Levi & Korsinsky by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) - ACCESS Newswire
The Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc. (ATNM) of a Class ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies Shareholders of Actinium - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - PR Newswire
Actinium enrolls first patient on the trial studying Iomab-ACT - TipRanks
Actinium Announces Enrollment of First Patient in the Iomab-ACT - GuruFocus
Actinium Pharmaceuticals (ATNM) Begins Pioneering Iomab-ACT Trial with CAR-T Therapy | ATNM Stock News - GuruFocus
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - Yahoo Finance
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Renaissance Technologies LLC Purchases 63,400 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Kirby McInerney LLP Urges Investors in Actinium - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders - PR Newswire
JPMorgan Chase & Co. Acquires 110,141 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to - Bluefield Daily Telegraph
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation - Kilgore News Herald
Actinium Pharmaceuticals Inc’s results are impressive - uspostnews.com
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM) - PR Newswire
The Attractiveness of Investing In Actinium Pharmaceuticals Inc (ATNM) is Growing - knoxdaily.com
Actinium Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Market Watch Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on an Downturn Note at 1.30 - DWinneX
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Actinium Presents Data Showing ATNM-400 is More Efficacious than - GuruFocus
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium - GlobeNewswire
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):